2024 年，非小细胞肺癌（NSCLC）治疗领域迎来了累累硕果。尤其是针对 EGFR 突变 III 期不可切除 NSCLC 的靶向巩固治疗研究，取得了令人振奋的突破性 ...

It shows how adjusting eGFR results for body surface may improve decision results. The National Kidney Foundation published a consensus document that advocates transition to race-free eGFR ...

Several targets almost fulfill this requisite: tenascin-C, podoplanin/aggrus, EGF receptor (EGFR), EGFRvIII ... extradomain B of fibronectin, integrin α v β 3, histone H1 complexed to ...

Integrins are very attractive therapeutic targets in oncology. The anti-tumor mechanisms of integrin-targeting drugs have been validated both in vitroand in vivo. Integrin-targeting drugs are ...